Zhuhai Drug Patent Portfolio
Zhuhai owns 1 orange book drug protected by 3 US patents Given below is the list of Zhuhai's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11419842 | Neutral pH compositions of Docetaxel and human serum albumin | 16 May, 2036 | Active |
| US12090134 | Neutral pH compositions of docetaxel and human serum albumin | 16 May, 2036 | Active |
| US12090135 | Neutral pH compositions of docetaxel and human serum albumin | 16 May, 2036 | Active |
Latest Legal Activities on Zhuhai's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Zhuhai.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Sep, 2025 | US11419842 |
| Recordation of Patent eGrant | 17 Sep, 2024 | US12090134 |
| Patent Issue Date Used in PTA Calculation | 17 Sep, 2024 | US12090135 |
| Recordation of Patent Grant Mailed | 17 Sep, 2024 | US12090134 |
| Patent eGrant Notification | 17 Sep, 2024 | US12090134 |
| Patent Issue Date Used in PTA Calculation | 17 Sep, 2024 | US12090134 |
| Recordation of Patent Grant Mailed | 17 Sep, 2024 | US12090135 |
| Email Notification | 17 Sep, 2024 | US12090135 |
| Recordation of Patent eGrant | 17 Sep, 2024 | US12090135 |
| Email Notification | 17 Sep, 2024 | US12090134 |
| Mail Patent eGrant Notification | 17 Sep, 2024 | US12090135 |
| Patent eGrant Notification | 17 Sep, 2024 | US12090135 |
| Mail Patent eGrant Notification | 17 Sep, 2024 | US12090134 |
| Email Notification | 29 Aug, 2024 | US12090135 |
| Email Notification | 29 Aug, 2024 | US12090134 |
Zhuhai's Family Patents
Clinical Trials
Recent Clinical Trials by Zhuhai:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD) | Zhuhai United Laboratories Co., Ltd. | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE1 |
| GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) | Eddingpharm (Zhuhai) Co., Ltd. | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
Zhuhai Drug List
Given below is the complete list of Zhuhai's drugs and the patents protecting them.
1. Beizray
Beizray is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11419842 | Neutral pH compositions of Docetaxel and human serum albumin |
16 May, 2036
(9 years from now)
| Active |
| US12090134 | Neutral pH compositions of docetaxel and human serum albumin |
16 May, 2036
(9 years from now)
| Active |
| US12090135 | Neutral pH compositions of docetaxel and human serum albumin |
16 May, 2036
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Beizray's drug page